Zhang Ying, Zhang Xiaowen, Wang Fang, Feng Yan, Tang Huaping
Department of Respiration Medicine, Qingdao Municipal Hospital, Qingdao, China.
Department of Traditional Chinese Acupuncture and Manipulation, Shandong University of Traditional Chinese Medicine, Jinan, China.
Open Med (Wars). 2021 Oct 25;16(1):1602-1607. doi: 10.1515/med-2021-0379. eCollection 2021.
Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC). In this report, we describe an NSCLC patient with BMs who survived for 58 months, which is the longest survival case among lung cancer patients with BMs. The patient was initially diagnosed with lung cancer more than 5 years ago with simultaneous brain, bone, and lung metastases. After gefitinib resistance, she received osimertinib in sequence with no progress for 58 months in total and maintained very good quality of life.
脑转移和骨转移严重影响肺癌患者的预后。如何优化现有靶向药物的使用是满足非小细胞肺癌（NSCLC）个体化治疗中中枢神经系统临床需求的重要途径。在本报告中，我们描述了一名患有脑转移的NSCLC患者，其存活了58个月，这是肺癌脑转移患者中存活时间最长的病例。该患者最初在5年多前被诊断为肺癌，同时伴有脑、骨和肺转移。在吉非替尼耐药后，她先后接受了奥希替尼治疗，总体无进展存活58个月，且生活质量维持良好。
